SAN DIEGO, June 4 /PRNewswire-FirstCall/ -- NuVasive, Inc. (Nasdaq: NUVA),
a medical device company focused on developing products for minimally
disruptive surgical treatments for the spine, announced today that Stephan S.
Ogilvie, Senior Director of Business Development, is scheduled to present at
the 8th Annual Needham Life Sciences Conference at the New York Palace Hotel
in New York, New York, on Thursday, June 11, 2009, at 11:00 a.m. Eastern Time.
A live webcast of the presentation will be available online from the
investor relations page of the Company's corporate website at
www.nuvasive.com. After the live webcast, the presentation will remain
available on the website for 30 days.
NuVasive is a medical device company focused on the design, development,
and marketing of products for the surgical treatment of spine disorders. The
Company's product portfolio is focused primarily on the $4.6 billion U.S.
spine implant market. Additionally, the Company has expanded into the $1.5
billion global biologics market, the $1.5 billion international market, and is
developing products for the emerging motion preservation market.
NuVasive's principal product offering is based on its Maximum Access
Surgery, or MAS(R) platform. The MAS platform combines four categories of
products that collectively minimize soft tissue disruption during spine
surgery with maximum visualization and safe, easy reproducibility for the
surgeon: NeuroVision(R), a proprietary software-driven nerve avoidance system;
MaXcess(R), a unique split-blade retractor system; a wide variety of
specialized implants; and several biologic fusion enhancers. MAS significantly
reduces surgery time and returns patients to activities of daily living much
faster than conventional approaches. Having redefined spine surgery with the
MAS platform's lateral approach, known as eXtreme Lateral Interbody Fusion, or
XLIF(R), NuVasive has built an entire spine franchise. With nearly 50 products
today spanning lumbar, thoracic and cervical applications, the Company will
continue to expand and evolve its offering predicated on its R&D focus and
dedication to outstanding service levels supported by a culture of Absolute
NuVasive cautions you that statements included in this press release that
are not a description of historical facts are forward-looking statements that
involve risks, uncertainties, assumptions and other factors which, if they do
not materialize or prove correct, could cause NuVasive's results to differ
materially from historical results or those expressed or implied by such
forward-looking statements. The potential risks and uncertainties that could
cause actual growth and results to differ materially include, but are not
limited to: the uncertain process of seeking regulatory approval or clearance
for NuVasive's products or devices, including risks that such process could be
significantly delayed; the possibility that the FDA may require significant
changes to NuVasive's products or clinical studies; the risk that products may
not perform as intended and may therefore not achieve commercial success; the
risk that competitors may develop superior products or may have a greater
market position enabling more successful commercialization; the risk that
additional clinical data may call into question the benefits of NuVasive's
products to patients, hospitals and surgeons; and other risks and
uncertainties more fully described in NuVasive's press releases and periodic
filings with the Securities and Exchange Commission. NuVasive's public filings
with the Securities and Exchange Commission are available at www.sec.gov.
NuVasive assumes no obligation to update any forward-looking statement to
reflect events or circumstances arising after the date on which it was made.
Kevin C. O'BoylePatrick F. Williams
EVP & Chief Financial Officer Vice President, Finance & Investor
NuVasive, Inc.NuVasive, Inc.
Jason RandoThe Ruth Group
SOURCE NuVasive, Inc.
/CONTACT: Kevin C. O'Boyle, EVP & Chief Financial Officer,
+1-858-909-1998, email@example.com; or for Investors: Patrick F.
Williams, Vice President, Finance & Investor Relations, +1-858-638-5511,
firstname.lastname@example.org, both of NuVasive, Inc.; or for Media: Jason
Rando of The Ruth Group, +1-646-536-7025, email@example.com/
/Web Site: http://www.nuvasive.com /
CO: NuVasive, Inc.; 8th Annual Needham Life Sciences Conference
ST: California, New York
IN: MEQ HEA MTC
-- NY27955 --
7955 06/04/200916:30 EDThttp://www.prnewswire.com